The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guideline update on the management of dyslipidemia continues to focus largely on how best to manage lipid levels to reduce cardiovascular (CV) risk. Although some things have remained the same, some important new recommendations have been added, based on evidence from several clinical trials published from 2019 onwards.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Ulcerative colitis
Rgs14 protein can worsen the severity
- Mastocytosis
Innovative pathogenesis-based therapeutic approaches in the pipeline
- Participation of the patient
Adherence in psychiatry
- Psychooncology
Communication as the key to therapy adherence
- From symptom to diagnosis
Renal cell carcinoma
- Lipid management: ESC/EAS guideline update 2025
New recommendations on CVD risk classification, lipid lowering in statin intolerance and hoFH
- Chronically active MS lesions
New paradigm in the diagnosis and treatment of multiple sclerosis
- Participation of the patient